Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Natalizumab in Russian RRMS Patients
NCT02142205Phase 4Completed
- Sponsor
- Biogen
- Start
- May 2012
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started May 2012; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02142205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142205.